Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 20:16:278-290.
doi: 10.17179/excli2016-846. eCollection 2017.

Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease

Golnaz Ekhlasi  1 , Mitra Zarrati  1 , Shahram Agah  2 , Agha Fatemeh Hosseini  3 , Sharieh Hosseini  4 , Shahrzad Shidfar  5 , Seyed Soroush Soltani Aarbshahi  1 , Elham Razmpoosh  6   7 , Farzad Shidfar  1   2   8
Affiliations

Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease

Golnaz Ekhlasi et al. EXCLI J. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) has been suggested to be well correlated with altered blood pressure. This study was conducted to determine the effects of symbiotic and vitamin E supplementation on blood pressure and inflammatory indices of patients with NAFLD. This randomized, double-blind, placebo-controlled trial was performed among 60 NAFLD patients aged 25 to 64 years old. Participants were randomly divided into four groups to receive a 400 IU alpha-tocopherol and 2 × 108 CFU/g symbiotic supplement for 8 weeks. The anthropometric parameters, systolic blood pressure (SBP) and diastolic blood pressure (DBP), serum malondialdehyde (MDA), nitric oxide (NO) and tumor necrosis factor α (TNFα) were assessed at baseline and after 8 weeks of intervention. After 8 weeks of intervention, combined symbiotic and alpha-tocopherol, symbiotic and alpha-tocopherol alone administration, compared with the placebo, resulted in significant decreases in SBP (-17.07±2.1, -16.07±3.56, -1.73±2.25 and -1.55±3.01 mmHg, P=0.01), serum MDA (-1.19±0.5, -0.12±0.65, 0.14 ± 0.64 and 0.16±0.34 nmol/mL, P<0.001), serum TNFα (-15.62±13.93, -9.24±7.12, -11.44 ± 15.47 and 3.01±1.71 pg/ml, P<0.001) concentrations. A significant decrease in serum AST (-11.36±4.52, -7.43±8.58, -5.93±6.61 and 2.5±5.75 μmol/L, P <0.001), ALT (-12.79±3.65, -3.66±6.81, -6.54±7.66 and 4.16±3.43 μmol/L, P <0.001) and ALP (-26.8±11.1, -4.56±9.22, -14.48±12.22 and 5.19±2.64 μmol/L, P <0.001) was seen. Variations in DBP and serum NO concentration were not significant. Alpha-tocopherol and symbiotic supplementation among patients with NAFLD resulted in decreased SBP, serum MDA, TNFα levels and enzymes liver; however, they did not affect DBP and serum NO concentration.

Keywords: NAFLD; alpha-tocopherol; blood pressure; nitric oxide; symbiotic.

PubMed Disclaimer

Figures

Table 1
Table 1. Baseline, end and change values of anthropometric indicators and blood pressure of study participants
Table 2
Table 2. Dietary intakes of study participants throughout the study
Table 3
Table 3. Baseline, end and change values of serum liver enzymes and some measured inflammatory factors of study participants
Table 4
Table 4. Adjusted changes in biochemical measurement and blood pressure in NAFLD patients that received symbiotic plus alpha-tocopherol, symbiotic and alpha-tocopherol supplements or placebo
Figure 1
Figure 1. Flow diagram of patient recruitment and randomization process
See this image and copyright information in PMC

References

    1. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J. 2006;82(967):315–322. - PMC - PubMed
    1. Albillos A, de la Hera A, Gonzalez M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology (Baltimore, Md) 2003;37:208–217. - PubMed
    1. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15:1090–1095. - PubMed
    1. Aqel B, DiBaise JK. Role of the gut microbiome in nonalcoholic fatty liver disease. Nutr Clin Pract. 2015;30:780–786. - PubMed
    1. Baradaran A, Nasri H, Rafieian-Kopaei M. Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants. J Res Med Sci. 2014;19:358–367. - PMC - PubMed

LinkOut - more resources